Comparison of the efficacy of subthreshold micropulse laser versus intravitreal anti-VEGF therapy for chronic central serous chorioretinopathy
Frontiers in Medicine · 30.04.2026 · 13
DOI: 10.3389/fmed.2026.1832055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 30.04.2026. Verfasst von Jinyu Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Pr…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To compare the therapeutic ability between 577-nm subthreshold micropulse laser (SML) and intravitreal anti-VEGF injection (IVA) in the treatment of chronic central serous chorioretinopathy (cCSCR).
Methods
The medical records of 50 cCSCR patients (50 eyes) who underwent SML (30 eyes) or IVA injection (20 eyes) were reviewed in this retrospective cohort study. Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), subretinal fluid (SRF), and subfoveal choroidal thickness (SFCT) measured by optical coherence tomography (OCT) at baseline, 1, 3, and 6 months post-treatment were extracted and compared between the two groups.
Results
Baseline demographic and clinical characteristics, including age, sex, leakage pattern on fluorescein angiography (FA), BCVA, CRT, SRF, and SFCT, were comparable between the two groups (all p > 0.05). The mean ± SD of SML sessions and IVA injection were 1.67 ± 0.80 and 1.75 ± 0.97, respectively ( p > 0.05). In comparison to the baseline values, BCVA showed statistically significant improvement at 6 months after treatment in both groups ( p < 0.05), while the CRT, SRF and SFCT values prominently decreased at the final evaluation (all p < 0.05). No statistically significant difference was revealed in the BCVA and CRT data of all time points between the two groups (all p > 0.05). At baseline, 1 month, and the 3 months, there was no statistically significant difference for the SRF and SFCT values between groups ( p > 0.05). However, at the 6th month, the SML group demonstrated significantly lower SRF, whereas the IVA group showed significantly lower SFCT (both p < 0.05).
Conclusion
Both SML and anti-VEGF has been confirmed effective in improving visual acuity and achieving anatomical recovery in patients with cCSCR. At 6 months, IVA was associated with greater reduction in SFCT, whereas SML achieved superior SRF resolution. These findings support individualized treatment selection based on disease characteristics and underlying pathophysiology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincia…
Zitieren
APA
Li, J., Zhu, T., Zhu, Y., Wang, Y., Wu, H., & Chen, Z. (2026). Comparison of the efficacy of subthreshold micropulse laser versus intravitreal anti-VEGF therapy for chronic central serous chorioretinopathy. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1832055
Vancouver
Li J, Zhu T, Zhu Y, Wang Y, Wu H, Chen Z. Comparison of the efficacy of subthreshold micropulse laser versus intravitreal anti-VEGF therapy for chronic central serous chorioretinopathy. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1832055
BibTeX
@article{Li2026,
author = {Li, Jinyu and Zhu, Tiepei and Zhu, Yanan and Wang, Yao and Wu, Haixiu and Chen, Zhiqing},
title = {Comparison of the efficacy of subthreshold micropulse laser versus intravitreal anti-VEGF therapy for chronic central serous chorioretinopathy},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1832055}
}
EUVIMED